Ahrens Investment Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Ahrens Investment Partners’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$12.3K	Buy	+15	New	+$11.3K	0.01%	576

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Ahrens Investment Partners's REGN Position: Q1 2023 in Review

Ahrens Investment Partners opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2023: 15 shares worth $12.3K. The stake represents 0.01% of the portfolio and ranks #576 among its holdings.

1,192 funds tracked by Wall St. Rank hold REGN as of Q1 2023.

Ahrens Investment Partners held 15 shares of Regeneron Pharmaceuticals worth $12.3K as of Q1 2023.
Regeneron Pharmaceuticals was a new Ahrens Investment Partners position in Q1 2023.
Regeneron Pharmaceuticals made up 0.01% of Ahrens Investment Partners's portfolio in Q1 2023, its #576 holding.
1,192 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2023.

Based on Ahrens Investment Partners's 13F filing for Q1 2023, filed 24 Apr 2023.